Antimicrobial therapy duration for bloodstream infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex : a retrospective cohort study
dc.contributor.author | Rodrigues, Rodrigo Douglas | pt_BR |
dc.contributor.author | Garcia, Rebeca Carvalho Lacerda | pt_BR |
dc.contributor.author | Bittencourt, Gabriel Almeida | pt_BR |
dc.contributor.author | Waichel, Vicente Bouchet | pt_BR |
dc.contributor.author | Garcia, Ester Carvalho Lacerda | pt_BR |
dc.contributor.author | Rigatto, Maria Helena da Silva Pitombeira | pt_BR |
dc.date.accessioned | 2024-10-22T06:56:30Z | pt_BR |
dc.date.issued | 2023 | pt_BR |
dc.identifier.issn | 2079-6382 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/280334 | pt_BR |
dc.description.abstract | Background: Ideal therapy duration for Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex (ABC) bloodstream infections (BSI) is not defined, especially in the context of carbapenem resistance. In this study, we compared short- (≤7 days) and long-term (>7 days) antimicrobial therapy duration for these infections. Methods: We performed a retrospective cohort study in two tertiary-care hospitals in Porto Alegre, Brazil, from 2013 to 2019. Eligible patients aged ≥18 years were included and excluded for the following criteria: polymicrobial infections, treatment with non-susceptible antibiotics, complicated infections, or early mortality (<8 days of active antimicrobial therapy). The 30-day mortality risk was evaluated using a Cox regression model. Results: We included 237 BSI episodes, 51.5% caused by ABC and 48.5% by Pseudomonas aeruginosa. Short-term therapy was not associated with 30-day mortality, adjusted hazard ratio 1.01, 95% confidence interval 0.47–2.20, p = 0.98, when adjusted for Pitt score (p = 0.02), Charlson Comorbidity Index score (p < 0.01), and carbapenem resistance (p < 0.01). Among patients who survived, short-term therapy was associated with shorter hospital stay (p < 0.01). Results were maintained in the subgroups of BSI caused by carbapenem-resistant bacteria (p = 0.76), ABC (p = 0.61), and Pseudomonas aeruginosa (p = 0.39). Conclusions: Long-term therapies for non-complicated Pseudomonas aeruginosa and ABC BSI were not superior to short-term therapy for 30-day mortality. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Antibiotics. Basel. Vol. 12, no. 3 (2023), 538, 10 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Bloodstream infections | en |
dc.subject | Sepse | pt_BR |
dc.subject | Acinetobacter baumannii-calcoaceticus complex | en |
dc.subject | Acinetobacter baumannii | pt_BR |
dc.subject | Treatment duration | en |
dc.subject | Pseudomonas aeruginosa | pt_BR |
dc.subject | Acinetobacter calcoaceticus | pt_BR |
dc.subject | Duração da terapia | pt_BR |
dc.title | Antimicrobial therapy duration for bloodstream infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex : a retrospective cohort study | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001206252 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (40090)Ciências da Saúde (10719)